A combined therapy improves survival in patients with metastatic melanoma

According to an international multicenter study published in the New England Journal of Medicine (NEJM), in which the Hospital Clínic has participated, the combined treatment with BRAF and MEK inhibitors increases survival in patients with metastatic melanoma. Dr. Ana Arance, senior specialist at the Medical Oncology Department (ICMHO), is one of the authors.